 STOCKHOLM, Jan. 11, 2023 PRNewswire BioArctic ABs publ Nasdaq Stockholm: BIOA B partner Eisai announced today that Eisai has submitted a marketing authorization application MAA for lecanemab Brand Name in the U.S.: LEQEMBITM, an investigational anti-amyloid beta Aβ protofibril antibody, for the treatment of early Alzheimers disease mild cognitive impairment due to Alzheimers disease AD ...... 